Histamine is the primary chemical that triggers an allergic reaction. It’s released from specialized immune cells within seconds of exposure to an allergen, and it’s directly responsible for the itching, swelling, redness, and sneezing that most people associate with allergies. But histamine doesn’t act alone. A cascade of other inflammatory chemicals amplifies and sustains the reaction, sometimes for hours after the initial exposure.
How Your Body Gets Primed in the First Place
An allergic reaction never happens on the very first encounter with an allergen. Instead, your immune system goes through a sensitization process that sets the stage for future reactions. When you’re first exposed to something like pollen, pet dander, or a food protein, immune cells process that substance and present it to a class of white blood cells called T helper cells. In people prone to allergies, those T helper cells shift into a mode that promotes the production of a specific antibody called IgE.
IgE antibodies are custom-built for that one allergen. Once produced, they circulate through the body and attach to the surface of mast cells, which are packed with chemical-filled granules and positioned throughout your skin, airways, and gut lining. This binding is what “arms” the mast cells. They’re now primed and waiting. The next time that same allergen shows up, it latches onto the IgE antibodies already sitting on the mast cell surface, and the cell dumps its contents in a burst called degranulation.
Histamine: The Immediate Trigger
Histamine is the most abundant chemical stored inside mast cell granules, and it’s the first one released during degranulation. It works by binding to receptors on nearby cells, primarily two types known as H1 and H2 receptors. The specific symptoms you experience depend on where in the body those receptors get activated.
In the skin, histamine stimulates H1 receptors to widen blood vessels, make them leaky, and trigger itching. That’s the mechanism behind hives. In the nose, H1 activation causes itching, swelling of the nasal lining, and sneezing. In the airways, it can trigger the bronchial tubes to constrict and the surrounding tissue to swell, two hallmarks of an asthma flare. H2 receptors, meanwhile, ramp up mucus production in the airways and gut.
During a severe, whole-body reaction like anaphylaxis, both receptor types fire simultaneously across multiple organ systems. H1 stimulation causes blood vessels to leak fluid into tissues and smooth muscles to contract, while H2 stimulation drives mucus secretion. Together, they can cause a dangerous drop in blood pressure.
How Histamine Makes Blood Vessels Leak
The swelling you see during an allergic reaction is caused by fluid escaping from blood vessels into surrounding tissue. Histamine drives this in two ways. First, it triggers the release of nitric oxide, which relaxes the smooth muscle around blood vessels, dilating them and increasing blood flow. More blood flowing through wider vessels means more fluid pushing outward. Second, histamine loosens the junctions between the cells lining blood vessel walls, particularly in small veins called venules. It does this by disrupting a protein called VE-cadherin that normally acts like a zipper holding those cells together. The combination of increased pressure from higher blood flow and a physically weaker vessel wall lets fluid pour into surrounding tissue, producing the puffiness, hives, or nasal congestion you feel.
The Second Wave: Leukotrienes and Prostaglandins
While histamine is pre-made and stored in granules, mast cells also manufacture a second set of chemicals on the spot during a reaction. These lipid-based molecules, called leukotrienes and prostaglandins, take a few minutes longer to appear but produce effects that are often more intense and longer-lasting than histamine alone.
Leukotrienes are potent airway constrictors. They tighten the muscles around bronchial tubes, slow the clearing of mucus, increase blood flow to inflamed tissue, and attract more immune cells to the area. In asthma, leukotrienes are considered a major driver of prolonged breathing difficulty. Prostaglandins contribute overlapping effects: more vessel dilation, more swelling, more mucus. Mast cells are the dominant source of one particular prostaglandin (PGD2) that basophils, the other main allergy cell circulating in the blood, do not produce.
This is why antihistamines alone don’t fully control asthma or severe allergic reactions. They block only one piece of a multi-chemical process.
Mast Cells vs. Basophils
Mast cells get most of the attention, but basophils, a type of white blood cell found in the bloodstream, also carry IgE on their surface and release histamine when triggered. The two cell types store slightly different chemical arsenals. Mast cells contain far more tryptase (a protein-cutting enzyme), produce a broader range of lipid mediators, and store the blood-thinning compound heparin in their granules. Basophils carry less tryptase, skip prostaglandin production entirely, and instead specialize in releasing signaling molecules like IL-4 and IL-13 that help sustain and shape the allergic response over time.
In practical terms, mast cells are the first responders stationed in tissues where allergens enter the body. Basophils arrive later from the bloodstream to reinforce the reaction.
The Late-Phase Response
Many people notice that allergic symptoms flare up again four to eight hours after the initial reaction, even without re-exposure to the allergen. This late-phase response is driven by a different set of chemicals: signaling proteins called cytokines, particularly IL-4, IL-5, and IL-13.
IL-13 plays an especially prominent role in the effector phase. It acts directly on structural cells in tissues, stimulating mucus-producing cells to multiply, causing smooth muscle to thicken, and altering the barrier function of the tissue lining. Over time, repeated late-phase reactions driven by IL-13 can lead to tissue remodeling, the kind of permanent airway thickening seen in chronic asthma.
IL-5, meanwhile, is the key signal that recruits eosinophils, a type of white blood cell that releases its own toxic proteins into tissue. Specific chemical messengers called RANTES and MIP-1alpha act as homing beacons, drawing eosinophils to the site of the allergic reaction in the lungs and airways. Eosinophil accumulation is a defining feature of allergic inflammation and a major contributor to tissue damage in chronic allergic diseases.
How Tryptase Confirms a Severe Reaction
Tryptase is a protein released alongside histamine from mast cell granules, and it serves as a useful marker for confirming that a severe reaction was truly allergic in nature. Blood levels peak one to two hours after the onset of anaphylaxis and can remain elevated for 12 to 24 hours. A level at or above 11.5 ng/mL suggests significant mast cell activation. Comparing an acute sample taken during the reaction to a baseline sample taken after recovery improves accuracy, catching roughly 71% of anaphylaxis cases compared to about 53% when using a fixed cutoff alone. Still, more than 30% of people with confirmed anaphylaxis never show elevated tryptase, so a normal result doesn’t rule it out.
How Epinephrine Shuts It Down
Epinephrine (the drug in auto-injectors like the EpiPen) is the direct chemical counterpart to the allergic cascade. It works within minutes by activating a completely different set of receptors on the same tissues that histamine and leukotrienes are attacking. Its effects on blood vessels cause them to constrict, reversing the dilation and leakiness that histamine triggered. It relaxes airway smooth muscle, reopening bronchial tubes that leukotrienes clamped shut. It strengthens the heart’s contractions and improves blood flow to the heart itself.
Critically, epinephrine also stabilizes mast cells, preventing them from releasing additional histamine, leukotrienes, and prostaglandins. This makes it uniquely effective: it doesn’t just oppose the symptoms, it slows the source. No other single treatment addresses the allergic cascade this broadly, which is why it remains the first-line intervention for anaphylaxis.